Latest 13F institutional holdings

Travelers Companies, Inc. filed its Q1 2026 13F holdings report, detailing a significant investment in Fidelis Insurance Holdings Limited.

Globe Life Inc. discloses its Q1 2026 investment holdings, primarily in Vanguard funds, with a total portfolio value of $380.8 million.

Commerce Bancshares Inc. has filed a 13F Notice for the quarter ended March 31, 2026, indicating no new holdings are reported in this filing.

NatWest Group plc has disclosed its institutional investment holdings as of March 31, 2026, in a Form 13F filing.

Federated Hermes, Inc. has submitted its Form 13F filing for the quarter ended March 31, 2026, detailing its institutional investment holdings.

LCNB Corp. has disclosed its institutional investment holdings as of March 31, 2026, detailing a diverse portfolio valued at over $297 million.

Arrow Financial Corp filed its quarterly 13F holdings report for the period ending March 31, 2026, detailing a total portfolio value of $994,008,270 across 278 holdings.

Citigroup Inc. has filed its quarterly Form 13F, reporting holdings across 11,050 securities with a total value of over $234 billion.

Cincinnati Financial Corp reports its institutional investment holdings for the quarter ended March 31, 2026, detailing a portfolio valued at over $4.96 billion.

ING GROEP NV has filed its quarterly Form 13F-HR report detailing its investment holdings as of March 31, 2026.

First Financial Bankshares Inc. discloses its equity holdings as of March 31, 2026, with a total portfolio value exceeding $4.95 billion.

Mitsubishi UFJ Financial Group Inc. disclosed significant holdings in Morgan Stanley through its 13F filing for the quarter ended March 31, 2026.

The Carlyle Group Inc. discloses its institutional investment holdings as of March 31, 2026, reporting a total portfolio value of approximately $10.62 billion.

Gilead Sciences reports $2.12 billion in equity holdings across six biotechnology investments as of March 31, 2026.

Walmart Inc. discloses its institutional investment holdings as of March 31, 2026, reporting a total portfolio value of approximately $840.36 million.

American International Group reports its institutional equity holdings as of March 31, 2026, totaling approximately $609.2 million.

Uber Technologies reports its institutional equity holdings as of March 31, 2026, totaling approximately $3.6 billion in market value.

Regeneron Pharmaceuticals discloses its equity investment portfolio as of March 31, 2026, featuring holdings in Adicet Bio and Intellia Therapeutics.

Fidelity National Financial, Inc. has filed its Q1 2026 13F-HR report, revealing a total portfolio value of over $2.7 billion across 21 holdings.

Home BancShares Inc. filed a Form 13F-NT indicating that its investment holdings are reported by another entity.

Sprott Inc. discloses a $3.44 billion investment portfolio focused heavily on precious metals, mining, and energy equities as of March 31, 2026.

American Express Company discloses a single equity holding in Global Business Travel Group, Inc. valued at approximately $880.4 million as of March 31, 2026.

BP PLC discloses a single equity holding in CME Group Inc. totaling $17.72 million as of March 31, 2026.

Central Securities Corp reports a $1.21 billion equity portfolio as of March 31, 2026, featuring major positions in Alphabet, Progressive, and Schwab.

Zions Bancorporation, National Association discloses its institutional equity holdings as of March 31, 2026.

PNC Financial Services Group, Inc. filed its quarterly Form 13F, revealing a diverse portfolio of holdings totaling over $157 billion.

Banco Santander, S.A. has filed its Form 13F for the quarter ended March 31, 2026, detailing its institutional investment holdings.

AlTi Global, Inc. has filed its Form 13F-HR for the quarter ended March 31, 2026, detailing its institutional investment holdings.

CVS Health Corp. has filed its quarterly 13F holdings report, detailing its investment portfolio as of March 31, 2026, with a total reported value of $212,255,190.

Sanofi's latest SEC filing reveals significant investments in several biotechnology companies, including Inhibrx Biosciences and MeiraGTx Holdings.